European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Winrevair, sotatercept, Date of authorisation: 22/08/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 19 June 2026 - 15:23

Human medicines European public assessment report (EPAR): Winrevair, sotatercept, Date of authorisation: 22/08/2024, Revision: 5, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Nobivac NXT HCPFeLV, feline calicivirosis, feline rhinotracheitis, feline panleucopenia (live) and feline leukemia (RNA replicon particle) vaccine, Status: Opinion

Submitted by Anonymous (not verified) on 19 June 2026 - 14:30

Veterinary medicines European public assessment report (EPAR): Nobivac NXT HCPFeLV, feline calicivirosis, feline rhinotracheitis, feline panleucopenia (live) and feline leukemia (RNA replicon particle) vaccine, Status: Opinion

Veterinary medicines European public assessment report (EPAR): Nobivac NXT HCPChFeLV, feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (RNA replicon particle) vaccine, Status: Opinion

Submitted by Anonymous (not verified) on 19 June 2026 - 14:30

Veterinary medicines European public assessment report (EPAR): Nobivac NXT HCPChFeLV, feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (RNA replicon particle) vaccine, Status: Opinion

EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia, Online, from 30 June 2026, 14:00 (CEST) to 30 June 2026, 18:00 (CEST)

Submitted by Anonymous (not verified) on 19 June 2026 - 13:31

EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia, Online, from 30 June 2026, 14:00 (CEST) to 30 June 2026, 18:00 (CEST)

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0298/2024

Submitted by Anonymous (not verified) on 19 June 2026 - 10:33

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0298/2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More